Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: GlobeNewswire
Patent estate covering atrioventricular interval modulation (“AVIM”) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that collectively comprise over 1,800 claims related to the treatment of hypertensionAVIM therapy is currently being studied in the BACKBEAT global pivotal study in collaboration with MedtronicOrchestra BioMed to provide detailed overview of AVIM therapy and the BACKBEAT global pivotal study in upcoming R&D day on June 11, 2024 in New York City NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the patent estate related to AVIM Therapy has reached 110 patents worldwide. The most recent patent was issued today, April 30, 2024. “We are very proud of the extensive intellectual property portfolio we have amassed related to our lead p
Show less
Read more
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswire
- Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024GlobeNewswire
- Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewswire
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of DirectorsGlobeNewswire